US Patent Issued to Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute on Oct. 14 for "DLL3-targeting antibodies and uses thereof" (New York Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,789, issued on Oct. 14, was assigned to Memorial Sloan Kettering Cancer Center (New York) and Tri-Institutional Therapeutics Discovery Institute (New York).

"DLL3-targeting antibodies and uses thereof" was invented by John T. Poirier (New York), Charles Rudin (New York), Jason Lewis (New York), Abdul Khan (New York), David Andrew (New York), Xinlei Chen (New York) and Ivo Lorenz (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present techno...